Exposure to environmental toxicants is associated with gut microbiome dysbiosis, insulin resistance and obesity.

Autor: Sen P; Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520, Turku, Finland; School of Medical Sciences, Faculty of Medicine and Health, Örebro University, 702 81, Örebro, Sweden., Fan Y; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark., Schlezinger JJ; Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA., Ehrlich SD; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3RX, UK., Webster TF; Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA., Hyötyläinen T; MTM Research Centre, School of Science and Technology, Örebro University, 702 81, Örebro, Sweden. Electronic address: tuulia.hyotylainen@oru.se., Pedersen O; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark; Center for Clinical Metabolic Research, Herlev-Gentofte University Hospital, Copenhagen, Denmark. Electronic address: oluf@sund.ku.dk., Orešič M; Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520, Turku, Finland; School of Medical Sciences, Faculty of Medicine and Health, Örebro University, 702 81, Örebro, Sweden. Electronic address: matej.oresic@oru.se.
Jazyk: angličtina
Zdroj: Environment international [Environ Int] 2024 Apr; Vol. 186, pp. 108569. Date of Electronic Publication: 2024 Mar 20.
DOI: 10.1016/j.envint.2024.108569
Abstrakt: Environmental toxicants (ETs) are associated with adverse health outcomes. Here we hypothesized that exposures to ETs are linked with obesity and insulin resistance partly through a dysbiotic gut microbiota and changes in the serum levels of secondary bile acids (BAs). Serum BAs, per- and polyfluoroalkyl substances (PFAS) and additional twenty-seven ETs were measured by mass spectrometry in 264 Danes (121 men and 143 women, aged 56.6 ± 7.3 years, BMI 29.7 ± 6.0 kg/m 2 ) using a combination of targeted and suspect screening approaches. Bacterial species were identified based on whole-genome shotgun sequencing (WGS) of DNA extracted from stool samples. Personalized genome-scale metabolic models (GEMs) of gut microbial communities were developed to elucidate regulation of BA pathways. Subsequently, we compared findings from the human study with metabolic implications of exposure to perfluorooctanoic acid (PFOA) in PPARα-humanized mice. Serum levels of twelve ETs were associated with obesity and insulin resistance. High chemical exposure was associated with increased abundance of several bacterial species (spp.) of genus (Anaerotruncus, Alistipes, Bacteroides, Bifidobacterium, Clostridium, Dorea, Eubacterium, Escherichia, Prevotella, Ruminococcus, Roseburia, Subdoligranulum, and Veillonella), particularly in men. Conversely, females in the higher exposure group, showed a decrease abundance of Prevotella copri. High concentrations of ETs were correlated with increased levels of secondary BAs including lithocholic acid (LCA), and decreased levels of ursodeoxycholic acid (UDCA). In silico causal inference analyses suggested that microbiome-derived secondary BAs may act as mediators between ETs and obesity or insulin resistance. Furthermore, these findings were substantiated by the outcome of the murine exposure study. Our combined epidemiological and mechanistic studies suggest that multiple ETs may play a role in the etiology of obesity and insulin resistance. These effects may arise from disruptions in the microbial biosynthesis of secondary BAs.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Matej Oresic reports financial support was provided by Research Council of Finland. Tuulia Hyotylainen reports financial support was provided by Novo Nordisk Foundation. Tuulia Hyotylainen reports financial support was provided by Swedish Research Council Formas. Tuulia Hyotylainen reports financial support was provided by Swedish Research Council. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: